Gastrointestinal Cancer | Specialty

IDEA Trial: 3 vs 6 Months of Adjuvant Therapy in CRC

July 13th 2017

Exploring Global Variations in Molecular Profiling

July 13th 2017

Maintenance and Second-Line Decisions in mCRC

July 13th 2017

Frontline Decisions in RAS Wild-Type Left-Sided mCRC

July 13th 2017

Nuances in Antibody Selection: Left Vs Right-Sided mCRC

July 13th 2017

Prognostic/Predictive Value of Tumor-Sidedness in CRC

July 13th 2017

Colorectal Cancer Prevention and Screening: An Update

July 13th 2017

Early- Versus Late-Onset Colorectal Cancer

July 13th 2017

Dr. Bekaii-Saab on the Potential Impact of Napabucasin Combo in Pancreatic Cancer

July 13th 2017

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the potential impact of the combination of napabucasin with gemcitabine and nab-paclitaxel in pancreatic cancer.

Dr. Lenz Discusses Targeted Combinations in Colorectal Cancer

July 13th 2017

Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses combinations with targeted agents in colorectal cancer.

Dr. Parikh on the Applicability of Liquid Biopsies in Gastrointestinal Cancers

July 12th 2017

Aparna R. Parikh, MD, medical oncologist, Massachusetts General Hospital, discusses the applicability of liquid biopsies in gastrointestinal cancers.

Dr. Pinato Discusses Pheochromocytomas and Paragangliomas

July 10th 2017

David J. Pinato, MD, PhD, NIHR Academic Clinical Lecturer in Medical Oncology, resident, Royal Brompton Hospital and Imperial College London, discusses pheochromocytomas and paragangliomas.

Dr. O'Neil on Next Steps for Napabucasin With FOLFIRI and Bevacizumab in CRC

July 10th 2017

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the next steps for napabucasin with FOLFIRI and bevacizumab (Avastin) as treatment for patients with colorectal cancer.

Dr. Bruix Discusses Progress of Second-Line Treatment in HCC

July 10th 2017

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the impact of the recent progress in the second-line treatment setting for hepatocellular carcinoma.

Dr. Huffman on Survival Analysis of Patients With Pseudopapillary Tumors of the Pancreas

July 7th 2017

Brandon Huffman, MD, resident physician, internal medicine, Mayo Clinic, discusses the survival analysis from a study of patients with solid pseudopapillary tumors of the pancreas.

Dr. Modest on Study of Surgical Intervention in CRC

July 6th 2017

Dominik P. Modest, MD, University of Munich, discusses an evaluation of resection in patients with metastatic colorectal cancer.

Dr. Ott on the CheckMate-032 Study in Gastric and GEJ Cancer

July 6th 2017

Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CheckMate-032 study in gastric and gastroesophageal junction cancer.

Biomarker Analysis Identifies Prognostic Markers for Aflibercept Efficacy in CRC

July 6th 2017

Ziv-aflibercept (Zaltrap) prolonged overall survival compared to placebo across subgroups of patients with metastatic colorectal cancer with wild-type and mutated RAS, KRAS, and BRAF genes.

CRC Patients With Liver Metastasis Receive Unanticipated Benefit From SIRT

July 6th 2017

While expected improvements in survival did not emerge with SIRT plus chemotherapy, an unanticipated benefit was observed with SIRT in patients with metastatic colorectal cancer.

Dr. Argiles on Study of Carcinoembryonic Antigen T-Cell Bispecific Antibody

July 5th 2017

Guillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses a carcinoembryonic antigen T-cell bispecific antibody.